The global TCR therapy market is estimated to grow from USD 0.03 billion in the current year to USD 4.13 billion by 2035, at a CAGR of 51% during the forecast period, till 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Target Indications
- Nasopharyngeal Carcinoma
- Multiple Myeloma
- Head and Neck Carcinoma
- Sarcoma
- Melanoma
- Acute Myeloid Leukemia
- Lung Cancer
- Ovarian Cancer
- Merkel Cell Cancer
Target Antigens
- NY-ESO-1
- EBV
- gp100
Key Players
- GlaxoSmithKline
- China Immunotech
- Xinqiao Hospital of Chongqing
- TCRCure Biopharma
- Adaptimmune Therapeutics
- Immunocore
- Intellia Therapeutics
- Takara Bio
- bluebird bio
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
Global TCR Therapy Market: Growth and Trends
Cancer continues to be one of the key areas of research and drug development within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity and several side effects including gastrointestinal and cardiovascular toxicities, drug developers are actively investigating targeted anti-cancer therapies. Of these, modified T-cell receptor (TCR) based therapies have emerged as a promising option. TCR therapy utilizes genetically modified lymphocytes to target specific tumor markers. TCR therapies have been demonstrated to selectively target and eliminate tumor cells from the body of a host with minimal treatment-related side effects. Notably, over 110 clinical trials related to TCR therapies have been registered in the past ten years, indicating substantial research activity. Driven by a promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is likely to witness significant growth in the mid to long-term.
Global TCR Therapy Market: Key Insights
The report delves into the current state of the global TCR therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:
- More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders.
- More than 90% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature; NY-ESO-1 and MAGE have emerged as the most popular target antigens.
- In the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR-based therapies; extensive efforts are underway to improve the successive generations of such therapies.
- Close to 60 scientists from renowned universities are presently involved in the clinical development of TCR-based therapies; majority of these KOLs are primarily based in the US and China.
- Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.
- A growing interest in this field is reflected from the increase in the partnership activity, involving both international and indigenous stakeholders; majority of the such deals were signed between players based in North America.
- Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion, across 140 instances.
- More than 75 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field.
- With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51%, in the next decade.
Global TCR Therapy Market: Key Segments
Currently, Multiple Myeloma Segment Occupies the Largest Share of the Global TCR Therapy Market
Based on target indication, the market is segmented into nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and Merkel cell cancer. At present, the multiple myeloma segment holds the maximum share of the global TCR therapy market. It is worth highlighting that the TCR therapy market for nasopharyngeal carcinoma is likely to drive the market in the near future.
NY-ESO-1 Target Antigen is Likely to Dominate the Global TCR Therapy Market During the Forecast Period
Based on the target antigen, the market is segmented into NY-ESO-1, EBV and gp100. Currently, NY-ESO-1 antigen holds the maximum share within the TCR therapy market. This trend is unlikely to change in the near future.
North America Accounts for the Largest Share of the Market
Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, and the Rest of the world. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.
Some Key Players in the Global TCR Therapy Market include:
- Adaptimmune Therapeutics
- Alaunos Therapeutics
- Bristol Myers Squibb
- Cellular Biomedicine
- Gilead Biosciences
- GlaxoSmithKline
- Immatics
- Immunocore
- Lion TCR
- Takara Bio
- Zelluna Immunotherapy
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
- Vice President, Immuno-Oncology, Celyad
- Vice President, Scientific Affairs, Kite Pharma
- Co-Founder and Chief Executive Officer, Lion TCR
- Chief Operating Officer, TxCell
Global TCR Therapy Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global TCR therapy market, focusing on key market segments, including [A] target indications, [B] target antigen, [C] key players and [D] geographical regions.
- Market Landscape: A comprehensive evaluation of TCR therapies, considering various parameters, such as [A] type of developer, [B] phase of development, [C] therapeutic area, [D] key target indication, [E] key target antigen, [F] source of T-cells, [G] route of administration, [H] dosing frequency, [I] target patient segment, [J] type of therapy and [K] most active players (in terms of number of TCR therapies). In addition, the chapter provides details on developer landscape of the industry and non-industry players.
- Popular Target Antigen Analysis: An in-depth analysis of popular target antigens, based on the number of TCR therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
- Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various t-cell receptor therapies based on parameters like [A] trial registration year, [B] enrolled patient population, [C] trial status, [D] trial phase, [E] target patient segment, [F] type of sponsor / collaborator, [G] most active players (in terms of number of registered trials), [H] key focus areas and [I] geography.
- Key Opinion Leader Analysis: An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with TCR therapies. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
- Drug Profiles: In-depth profiles of marketed and mid- to late-stage clinical products (phase I/II or above), focusing on [A] overview of the therapy, [B] its mechanism of action, [C] dosage information, [D] details on the cost and sales information (wherever available), [E] a clinical development plan, and [F] clinical trial results.
- Company Profiles: In-depth profiles of key industry players in TCR therapies market, focusing on [A] company overviews, [B] product portfolio, [C] technology portfolio (if available), [D] strategic / venture capital investments made in these companies, [E] an insightful recent development related to TCR therapies, and [F] future outlook.
- Partnerships and Collaborations: An analysis of partnerships established in this sector, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others.
- Funding and Investment Analysis: A detailed evaluation of the investments made into the companies having proprietary T-cell receptor candidates / technologies, encompassing seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
- Patent Analysis: Detailed analysis of various patents filed / granted related to TCR therapies based on [A] type of patent, [B] patent publication year, [C] geographical distribution, [D] Cooperative Patent Classification (CPC) symbols, [E] emerging focus area, [F] type of player, [G] leading player (in terms of number of patents), and [H] patent benchmarking. It also includes a detailed valuation analysis.
- Case Study: A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
- Cost Price Analysis: A comprehensive discussion on the various factors that are likely to influence the pricing of cell-based therapies. This includes an exploration of different models and approaches that pharmaceutical companies may consider while determining the prices of their lead therapy candidates that are likely to be marketed in the near future.
- Promotional Analysis: A review of the key promotional strategies that are being implemented by the developers of the approved TCR therapy (Kimmtrak®).
Key Questions Answered in this Report
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adaptimmune Therapeutics
- Alaunos Therapeutics
- Bristol Myers Squibb
- Cellular Biomedicine
- Gilead Biosciences
- GlaxoSmithKline
- Immatics
- Immunocore
- Lion TCR
- Takara Bio
- Zelluna Immunotherapy
Methodology
LOADING...
